1. Home
  2. SLM vs PTCT Comparison

SLM vs PTCT Comparison

Compare SLM & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SLM Corporation

SLM

SLM Corporation

HOLD

Current Price

$27.95

Market Cap

5.5B

Sector

Finance

ML Signal

HOLD

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$76.81

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLM
PTCT
Founded
1972
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
5.3B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
SLM
PTCT
Price
$27.95
$76.81
Analyst Decision
Buy
Buy
Analyst Count
13
17
Target Price
$32.54
$73.76
AVG Volume (30 Days)
3.6M
1.2M
Earning Date
01-22-2026
02-26-2026
Dividend Yield
1.88%
N/A
EPS Growth
N/A
N/A
EPS
2.84
8.94
Revenue
$1,460,617,000.00
$1,779,150,000.00
Revenue This Year
$6.00
$127.32
Revenue Next Year
$17.94
N/A
P/E Ratio
$9.74
$8.64
Revenue Growth
N/A
97.54
52 Week Low
$23.81
$35.95
52 Week High
$34.97
$87.50

Technical Indicators

Market Signals
Indicator
SLM
PTCT
Relative Strength Index (RSI) 53.20 52.19
Support Level $27.22 $74.22
Resistance Level $28.23 $79.10
Average True Range (ATR) 0.55 2.12
MACD 0.08 -0.16
Stochastic Oscillator 83.62 50.16

Price Performance

Historical Comparison
SLM
PTCT

About SLM SLM Corporation

SLM Corp is an education solutions company. It business is to originate and service loans to students and their families to finance the cost of their education. The provide Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.

Share on Social Networks: